Hematology Malignancy Innovations in Clinical Trials

UH Seidman Cancer Center - Innovations in Clinical Trials - publication cover

Current Issue:

JAN1A14: VMP +/- Daratumumab for untreated myeloma patients.
S1211: Elotuzumab and Bortezomib, Dexamethasone and Lenalidomide for newly diagnosed high-risk myeloma patients.
CASE4A13: Ixazomib (MLN9708) plus Panobinostat and Dexamethasone for relapsed myeloma
CASE1A09: Very low dose continuous azacytidine plus lenalidomide and dexamethasone for relapsed multiple myeloma.
E3A06: Lenalidomide for patients with high-risk smoldering myeloma
MLNM2A13: Ixazomib, lenalidomide and dexamethasone for newly diagnosed multiple myeloma
MLNM1A15: Ixazomib maintenance after induction therapy for patients ineligible for autologous transplantation

MESO 1Z12: MSC Expanded Umbilical Cord Blood Transplant
CTN 1101: Umbilical Cord Blood vs. Haploidentical Transplants
BELL 1Z12: Haploidentical SCT with Genetically Modified T Cells to Stop GVHD
UNMC 1413: Lenalidomide Maintenance After Autologous SCT
CASE 9Z13: Targeted Marrow Irradiation in Reduced Intensity Stem Cell Transplant
CCASE 12Z13: Allogeneic Transplant for Patients with Sickle Cell Anemia
CASE 5913: Curcumin and Vitamin D for Patients with Early-Stage CLL Or SLL
PRE 1413: Rituximab vs. Obinotuzumab for Patients with Low-Burden, Advanced-Stage Follicular Lymphoma

Treatment of High Risk Smoldering Myeloma
BCL2 Inhibition for High Risk Relapsed CLL
Lenalidomide plus R-CHOP for DLBCL
Methoxyamine and Temozolomide in Patients with Advanced Solid Tumors
Vaccine Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Treatment of Renal Tumors in Poor Surgical Candidates